9 Best Performing European Stocks to Invest In

4. AstraZeneca PLC (NASDAQ:AZN)

Year-to-Date Performance: 24.01%

Number of Hedge Fund Holders: 48

AstraZeneca PLC (NASDAQ:AZN) ranks among the best-performing European stocks to invest in. Following the release of Phase 3 trial data for baxdrostat at ESC 2025, Goldman Sachs reaffirmed its Conviction Buy rating on AstraZeneca PLC (NASDAQ:AZN) on September 1. The Phase 3 BaxHTN trial found that baxdrostat reduced seated systolic blood pressure (SBP) in a dose-dependent, placebo-adjusted manner at week 12.

According to safety data, both the 2 mg and 1 mg doses had confirmed rates of moderate to severe hyperkalemia of 1.1%, while the placebo had a rate of 0%. Compared to 1.9% with a placebo, discontinuation owing to adverse reactions occurred at rates of 4.5% for the 2 mg dose and 2.7% for the 1 mg dose.

Management stated during its conference call that baxdrostat did not have any clinically significant drug-drug interactions, which is a significant finding for the treatment’s possible use in clinical trials.

AstraZeneca PLC (NASDAQ:AZN) is a prominent player in the pharmaceutical sector, especially for its work on rare disease and cancer treatments. The company has a strong reputation in the healthcare industry thanks to its history of medical advancements.